We have previously reported that cediranib, a RTK inhibitor targeting VEGF and PDGF receptor signaling was largely unable to provide an effective therapeutic benefit in an intracranial mouse glioma model [19], [20]. The gene discussed is VEGFA; the disease is central nervous system cancer.